Indomethacin Treatment in Patent Ductus arteriosus
Developmental Pharmacology and Therapeutics · 2019
DOI: 10.1159/000455530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Pharmacology and Therapeutics, 2019. Verfasst von Richard M. Nestrud und 7 weiteren Autor:innen. Die Arbeit wurde bisher 33-mal zitiert (Crossref).
Abstract (Originalsprache)
23 premature infants were placed on a randomized double-blind study to evaluate the effectiveness of indomethacin in closing a patent ductus arteriosus. Infants received 0. 2 mg/kg indomethacin or placebo by gavage. In the trea tment group, 7 patients responded out of a total of 12, while in the placebo group, 2 responded out of a total of 11. lndomethacin plasma levels were obtained in 6 patients in the treatment group. Plasma levels showed markcd variability in peak level (60-3,100 ng/ml), time to peak level (0.5-6 h) and t1/2 (1 to > 24 h).
Zitieren
APA
Nestrud, R. M., Hill, D. E., Arrington, R. W., Beard, A. G., Dungan, W. T., Lau, P., Norton, J., & Readinger, R. I. (2019). Indomethacin Treatment in Patent Ductus arteriosus. Developmental Pharmacology and Therapeutics. https://doi.org/10.1159/000455530
Vancouver
Nestrud RM, Hill DE, Arrington RW, Beard AG, Dungan WT, Lau P, et al. Indomethacin Treatment in Patent Ductus arteriosus. Developmental Pharmacology and Therapeutics. 2019. doi:10.1159/000455530
BibTeX
@article{Nestrud2019,
author = {Nestrud, Richard M. and Hill, Donald E. and Arrington, Robert W. and Beard, Alice G. and Dungan, William T. and Lau, Pui-Yan and Norton, J.B. and Readinger, Richard I.},
title = {Indomethacin Treatment in Patent Ductus arteriosus},
journal = {Developmental Pharmacology and Therapeutics},
year = {2019},
doi = {10.1159/000455530}
}
EUVIMED